Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review

Döme, Péter; Tombor, László; Lazáry, Judit; Gonda, Xénia; Rihmer, Zoltán

doi:10.1016/j.brainresbull.2018.12.015

Cited by 45 publications

(29 citation statements)

References 396 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, the clinical use of these drugs is limited by their characteristic side effects and poor tolerability profile [ 13 ]. Several natural compounds are being considered for their possible role in the treatment of mood disorders, including saffron, St John’s wort, tryptophan and omega-3 fatty acids, among others [ 14 , 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Antianhedonic and Antidepressant Effects of Affron®, a Standardized Saffron (Crocus Sativus L.) Extract

et al. 2020

View full text Add to dashboard Cite

Anxiety and depression have high prevalence in the general population, affecting millions of people worldwide, but there is still a need for effective and safe treatments. Nutritional supplements have recently received a lot of attention, particularly saffron. Thus, several pre-clinical studies support a beneficial role for bioactive compounds, such as saffron, in anxiety and depression. Here we used an animal model of depression based on social isolation to assess the effects of affron®, a standardized saffron extract containing ≥3.5% of total bioactive compounds safranal and crocin isomers. Affron® was administered both through the oral and the intraperitoneal routes, and several tasks related to anxiety and depression, such as the elevated plus maze, the forced swimming test or the sucrose preference test, were assessed. These tasks model key features of depressive states and anxious states relating to fear, behavioral despair or anhedonia, the lack of motivation and/or pleasure from everyday activities, respectively. Animals receiving oral affron® displayed behaviors congruent with improvements in their anxious/depressive state, showing the enhanced consumption of a sweet solution, as well as an increase in certain escape responses in the forced swimming test. Our data support a beneficial role for oral saffron in anxious/depressive states.

show abstract

Section: Introductionmentioning

confidence: 99%

Antianhedonic and Antidepressant Effects of Affron®, a Standardized Saffron (Crocus Sativus L.) Extract

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In nonplacebo-controlled studies, the evidence has been promising. In the two main placebo-controlled studies done, one has T A B L E 3 Newer pharmacotherapy for TTM 10,20,21,[42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61] Drug name shown significant benefit over placebo while a second trial has not. [44][45][46] In a 2009 double-blind placebo-controlled trial studying NAC use in 50 adults with TTM, NAC 1200 mg twice daily was found to show significant benefit over placebo.…”

Section: N-acetylcysteinementioning

confidence: 99%

“…Additionally, alteration of neurotrophic factor gene expression, short-chain fatty acid-mediated modulation of G-proteincoupled receptors, and changes in the hypothalamic-pituitary axis are thought to play a role. 54,55 Animal studies have shown that gut microbiota may also affect mammalian brain development, including development of the striatum, which has (among other areas of the brain) been shown to have structural abnormalities in patients with TTM. 10,56,57 A possible relationship however would require further investigation prior to any in-depth discussion.…”

Section: Probioticsmentioning

confidence: 99%

“…These include effects on vagus nerve signaling (possibly through serotonin synthesis of enterochromaffin cells), mineral metabolism, modulation of circulating cytokine levels, and changes in neurotransmitter turnover. Additionally, alteration of neurotrophic factor gene expression, short‐chain fatty acid‐mediated modulation of G‐protein‐coupled receptors, and changes in the hypothalamic‐pituitary axis are thought to play a role 54,55 …”

Section: Newer Pharmacotherapy For Ttmmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in the treatment of trichotillomania (hair‐pulling disorder)

Everett

Jafferany

Skurya

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Trichotillomania (TTM) is a condition in which affected individuals pull out their hair resulting in hair loss. This disorder affects roughly 0.5% to 2.0% of the population and can have significant psychological morbidity. Behavioral therapy has been used with success in the treatment of TTM, but not all patients are willing or able to comply with this treatment strategy. There is a need for effective pharmacological treatment options. Historically, pharmacotherapy for TTM has been inadequate in most cases, but recent advances have been made in this regard. Fluoxetine, clomipramine, olanzapine, and naltrexone have all been used in the treatment of TTM, but evidence of benefit has varied, and side effect profiles can limit practical utility. Recent advances in the understanding of the pathophysiology of TTM, as well as evidence of benefit seen with some glutamate-modulating agents such as N-acetylcysteine and dronabinol, have provided newer potential pharmacotherapy options.

show abstract

“…Typically, these pharmaceutical drugs are divided into four main classes: tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitor (SSRI), selective noradrenaline reuptake inhibitor (SNRI), and monoamine oxidase inhibitors (MOI) [4]. Although there are several different medicines commercially available, most of them have similar side effects (mainly in the early stages of administration), and a slow time to start acting on the human brain [5]. Besides these, other medications, such as antiepileptic drugs, can also be used to treat such disorders since they can act as mood stabilizers in some cases [6].…”

Section: Introductionmentioning

confidence: 99%

Multidimensional Liquid Chromatography Employing a Graphene Oxide Capillary Column as the First Dimension: Determination of Antidepressant and Antiepileptic Drugs in Urine

et al. 2020

View full text Add to dashboard Cite

Human mental disorders can be currently classified as one of the most relevant health topics. Including in this are depression and anxiety, which can affect us at any stage of life, causing economic and social problems. The treatments involve cognitive psychotherapy, and mainly the oral intake of pharmaceutical antidepressants. Therefore, the development of analytical methods for monitoring the levels of these drugs in biological fluids is critical. Considering the current demand for sensitive and automated analytical methods, the coupling between liquid chromatography and mass spectrometry, combined with suitable sample preparation, becomes a useful way to improve the analytical results even more. Herein we present an automated multidimensional method based on high-performance liquid chromatography-tandem mass spectrometry using a lab-made, graphene-based capillary extraction column connected to a C8 analytical column to determined five pharmaceutical drugs in urine. A method enhancement was performed by considering the chromatographic separation and the variables of the loading phase, loading time, loading flow, and injection volume. Under optimized conditions, the study reports good linearity with R2 > 0.98, and limits of detection in the range of 0.5–20 µg L−1. Afterward, the method was applied to the direct analysis of ten untreated urine samples, reporting traces of citalopram in one of them. The results suggest that the proposed approach could be a promising alternative that provides direct and fully automated analysis of pharmaceutical drugs in complex biological matrices.

show abstract

Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review

Cited by 45 publications

References 396 publications

Antianhedonic and Antidepressant Effects of Affron®, a Standardized Saffron (Crocus Sativus L.) Extract

Antianhedonic and Antidepressant Effects of Affron®, a Standardized Saffron (Crocus Sativus L.) Extract

Recent advances in the treatment of trichotillomania (hair‐pulling disorder)

Multidimensional Liquid Chromatography Employing a Graphene Oxide Capillary Column as the First Dimension: Determination of Antidepressant and Antiepileptic Drugs in Urine

Contact Info

Product

Resources

About